A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Aplastic Anemia

Interventions

DRUG: Eltrombopag
DRUG: hATG
DRUG: CsA

Sponsor

Novartis Pharmaceuticals